U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. How Drugs are Developed and Approved
  5. Types of Applications
  6. Abbreviated New Drug Application (ANDA)
  7. Generic Drugs Program Activities Report - Monthly Performance
  1. Abbreviated New Drug Application (ANDA)

Generic Drugs Program Activities Report - Monthly Performance

GDUFA YEAR/
Actions This Month		 20-Oct 20-Nov 20-Dec 21-Jan 21-Feb 21-Mar 21-Apr 21-May 21-Jun 21-Jul 21-Aug 21-Sep FY-2021
Refuse to Receive (RTR) - Originals 3 6 0 1 7 4 3 11 *       35
Standard - GDUFA II 2 5 0 0 7 2 3 8 *       27
Priority - GDUFA II 1 1 0 1 0 2 0 3 *       8
GDUFA I 0 0 0 0 0 0 0 0 *       0
Acknowledgement - Original 52 47 31 57 88 61 70 85 *       491
Refuse to Receive (RTR) - PAS 0 0 0 0 0 0 1 0 *       1
Withdrawals  (all original ANDAs) 7 36 9 23 36 9 17 7 *       144
Approved ANDA 2 21 0 12 24 0 7 0 *       66
Unapproved ANDA 5 15 9 11 12 9 10 7 *       78
Withdrawals  (PAS) 5 5 5 3 9 0 5 5 *       37
Approvals  78 55 63 62 72 63 55 46 45       539
First Time Generics 9 3 7 5 16 8 11 5 9       73
 Not First Time Generics 69 52 56 57 56 55 44 41 36       466
First Cycle Approvals 19 7 10 17 9 17 8 7 *       94
Not First Cycle Approvals 59 48 53 45 63 46 47 39 *       400
Tentative Approvals  15 21 22 8 7 11 17 12 17       130
First Cycle Tentative Approvals (included above) 3 4 2 1 0 2 2 3 *       17
Complete Responses (CR) 167 171 154 157 183 140 149 127 125       1373
Information Requests (IR) 359 334 370 307 416 409 383 357 *       2935
Originals 215 184 203 177 236 258 220 216 *       1709
Supplements 144 150 167 130 180 151 163 141 *       1226
Discipline Review Letters (DRL) 199 166 168 131 158 204 159 163 *       1348
Drug Master File Completeness Assessment (DMF CA) 52 73 59 58 43 43 23 27 *       378
GDUFA YEAR (Receipts)
Submissions This Month		 20-Oct 20-Nov 20-Dec 21-Jan 21-Feb 21-Mar 21-Apr 21-May 21-Jun 21-Jul 21-Aug 21-Sep FY-2021
Abbreviated New Drug Applications (ANDA) + 20 40 124 36 50 131 60 41 76       578
Amendments 176 204 292 179 191 235 217 171 *       1665
Major 77 88 152 91 83 103 99 84 *       777
Minor 51 81 79 45 55 71 53 47 *       482
Unsolicited Amendments ++ 48 35 61 43 53 61 65 40 *       406
Pre-Submission Facility Correspondence 12 3 3 6 3 2 3 1 *       33
CBE Supplements  958 961 787 611 562 844 832 1018 *       6573
PAS Supplements +++ 126 112 122 83 101 120 124 101 *       889
DMFs - Type II 34 63 90 25 46 93 50 45 *       446
GDUFA YEAR (Receipts) 20-Oct 20-Nov 20-Dec 21-Jan 21-Feb 21-Mar 21-Apr 21-May 21-Jun 21-Jul 21-Aug 21-Sep FY-2021
Controls ++++ 312 305 280 329 371 402 298 299 *       2596
Requests for Clarfication 3 2 3 1 1 7 3 2 *       22
Post CR Meeting Requests This Month 8 5 2 3 7 8 5 8 *       46

 

NOTE: Numbers reflect current data at the time of posting and may change based on refreshed counts in our tracking systems, including application status updates.
These numbers are not intended for Congressional reporting purposes.

* = This data requires additional verification and will be posted when available.
+ = Original Receipts are reported as raw receipts (versus filed receipts).
++ = Due to system capabilities, counts for unsolicited amendments were previously based on amendments submitted after a tentative approval was issued. Starting in Oct. 2019 (FY 2020) the monthly metric report now captures all unsolicited amendments submitted to the agency.
+++ = PAS Supplements do not include REMS PAS supplements.
++++ = Controls count only those requests deemed appropriate for a control.         

Previous Activities Reports

 

 

Back to Top